Results from the DELIVER study with VYEPTI® (eptinezumab-jjmr) has been published in a top-ranking medical journal
The primary and key secondary results on VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures are now published in the high-impact medical journal Lancet Neurology.
0
ABOUT THE NEWSROOM
Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.
